Analysts forecast that Curis, Inc. (NASDAQ:CRIS) will report $2.30 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Curis’ earnings, with estimates ranging from $2.19 million to $2.40 million. Curis reported sales of $2.13 million in the same quarter last year, which indicates a positive year-over-year growth rate of 8%. The company is scheduled to announce its next earnings report on Thursday, May 3rd.
On average, analysts expect that Curis will report full year sales of $2.30 million for the current fiscal year, with estimates ranging from $8.96 million to $10.40 million. For the next fiscal year, analysts anticipate that the firm will report sales of $10.79 million per share, with estimates ranging from $9.48 million to $12.10 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Curis.
Curis (NASDAQ:CRIS) last posted its quarterly earnings results on Thursday, March 8th. The biotechnology company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.04. Curis had a negative net margin of 538.66% and a negative return on equity of 250.55%. The business had revenue of $3.26 million during the quarter, compared to analyst estimates of $2.03 million. During the same quarter in the previous year, the business posted ($0.08) EPS.
Separately, Zacks Investment Research lowered shares of Curis from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $7.00.
Shares of NASDAQ:CRIS traded down $0.04 during trading hours on Thursday, hitting $0.54. The company’s stock had a trading volume of 1,458,022 shares, compared to its average volume of 2,909,760. Curis has a 52 week low of $0.47 and a 52 week high of $2.72. The company has a debt-to-equity ratio of 1.49, a quick ratio of 4.56 and a current ratio of 4.56. The firm has a market cap of $88.61, a P/E ratio of -1.49 and a beta of 1.29.
Several hedge funds and other institutional investors have recently bought and sold shares of CRIS. Thrivent Financial For Lutherans bought a new position in shares of Curis during the 4th quarter worth approximately $108,000. SG Americas Securities LLC raised its stake in shares of Curis by 514.0% during the 4th quarter. SG Americas Securities LLC now owns 269,128 shares of the biotechnology company’s stock worth $188,000 after acquiring an additional 225,295 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Curis by 8.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 100,023 shares of the biotechnology company’s stock worth $190,000 after acquiring an additional 8,102 shares in the last quarter. Citadel Advisors LLC raised its stake in shares of Curis by 912.0% during the 4th quarter. Citadel Advisors LLC now owns 321,400 shares of the biotechnology company’s stock worth $225,000 after acquiring an additional 289,640 shares in the last quarter. Finally, Two Sigma Advisers LP raised its stake in shares of Curis by 1,591.5% during the 4th quarter. Two Sigma Advisers LP now owns 331,922 shares of the biotechnology company’s stock worth $232,000 after acquiring an additional 312,299 shares in the last quarter. Hedge funds and other institutional investors own 47.66% of the company’s stock.
TRADEMARK VIOLATION WARNING: “$2.30 Million in Sales Expected for Curis, Inc. (CRIS) This Quarter” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another website, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/08/2-30-million-in-sales-expected-for-curis-inc-cris-this-quarter.html.
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
Get a free copy of the Zacks research report on Curis (CRIS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.